Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 902 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $47.92, for a total transaction of $43,223.84. Following the completion of the sale, the senior vice president now owns 3,524 shares of the company's stock, valued at $168,870.08. This trade represents a 20.38 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Jolanda Howe also recently made the following trade(s):
- On Tuesday, January 7th, Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total transaction of $32,115.00.
- On Thursday, November 14th, Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.10, for a total value of $117,750.00.
Mirum Pharmaceuticals Trading Up 2.0 %
MIRM stock opened at $48.48 on Tuesday. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a 52-week low of $23.14 and a 52-week high of $49.40. The company's 50-day simple moving average is $43.76 and its 200-day simple moving average is $41.61. The firm has a market cap of $2.33 billion, a P/E ratio of -24.00 and a beta of 0.98.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. The company had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. Mirum Pharmaceuticals's quarterly revenue was up 89.4% compared to the same quarter last year. During the same period last year, the company earned ($0.57) earnings per share. As a group, equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.45 EPS for the current fiscal year.
Institutional Investors Weigh In On Mirum Pharmaceuticals
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Frazier Life Sciences Management L.P. lifted its holdings in Mirum Pharmaceuticals by 1.2% during the third quarter. Frazier Life Sciences Management L.P. now owns 6,570,392 shares of the company's stock valued at $256,245,000 after purchasing an additional 75,000 shares in the last quarter. State Street Corp lifted its stake in Mirum Pharmaceuticals by 19.9% in the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company's stock valued at $69,955,000 after buying an additional 297,511 shares in the last quarter. Geode Capital Management LLC lifted its stake in Mirum Pharmaceuticals by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 936,197 shares of the company's stock valued at $36,519,000 after buying an additional 29,017 shares in the last quarter. Lord Abbett & CO. LLC acquired a new stake in Mirum Pharmaceuticals in the 3rd quarter worth about $28,913,000. Finally, Clearbridge Investments LLC increased its stake in Mirum Pharmaceuticals by 165.5% during the 2nd quarter. Clearbridge Investments LLC now owns 699,933 shares of the company's stock worth $23,931,000 after buying an additional 436,349 shares in the last quarter.
Analyst Upgrades and Downgrades
Several analysts have weighed in on MIRM shares. Leerink Partners boosted their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an "outperform" rating in a research note on Thursday, October 17th. Citigroup upped their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Robert W. Baird raised their price target on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 13th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $57.10.
View Our Latest Stock Analysis on MIRM
About Mirum Pharmaceuticals
(
Get Free Report)
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.